Protocolized REDUction of Non-Resuscitation Fluids in SEptic Shock Patients. A Protocol for the REDUSE Randomized Clinical Trial.
Peter Bentzer, Anja Lindén, Markus H Olsen...
https://pubmed.ncbi.nlm.nih.gov/40671283/Actively Recruiting
Led by Region Skane · Updated on 2026-10-06
1850
Participants Needed
22
Research Sites
26 weeks
Total Duration
Researchers are evaluating the effects of a restrictive strategy for giving non-resuscitation fluids to adult patients with septic shock. This trial aims to compare a protocolized reduction of these fluids against usual care to assess both beneficial and harmful impacts on patients during intensive care. The study focuses on adults who meet specific septic shock criteria, including infection suspicion, elevated plasma lactate, and need for vasopressors. Participants are randomly assigned to one of two groups. In the experimental group, non-resuscitation fluids are given according to a strict protocol that starts within two hours of randomization and continues during the ICU stay, up to 90 days. This protocol includes guidelines about maintenance fluids, intravenous and enteral hydration, nutrition, glucose use, and medication concentration. The other group receives fluids according to local standard practices with some general guidelines. Both groups are monitored throughout their ICU admission. During the study, participants undergo regular assessments including survival status at 90 days, complications in the ICU, and number of days free from mechanical ventilation within 90 days. Researchers also evaluate cognitive function and health-related quality of life six months after inclusion. The trial uses triple masking and follows participants from enrollment through ICU discharge and beyond, with the total participation lasting up to several months depending on individual outcomes.
CONDITIONS
Protocolized Reduction of Non-resuscitation Fluids Versus Usual Care in Septic Shock Patients
P
Peter Bentzer
J
Jane Fisher
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Region Skane
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 12 hours after ICU admission
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 90 days or until ICU discharge
Participants receive either a protocolized reduction of non-resuscitation fluids or usual fluid care according to local routines during their ICU stay.
Continuous monitoring during ICU admission
Duration - Up to 6 months after inclusion
Participants are monitored for survival, ICU complications, mechanical ventilation-free days, cognitive function, and quality of life up to six months after inclusion.
Scheduled assessments at 90 days and 6 months
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Peter Bentzer, Anja Lindén, Markus H Olsen...
https://pubmed.ncbi.nlm.nih.gov/40671283/Region Skane
Lead Sponsor